PetVivo Holdings

What PetVivo Holdings does

PetVivo Holdings, Inc. is a publicly traded biomedical device company (OTCQX: PETV) headquartered in Minneapolis, Minnesota, focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals. The company's flagship product is Spryng with OsteoCushion Technology, an intra-articular injectable veterinary medical device composed of sterilized extra-cellular matrix microparticles that absorb onto the joint synovial lining and integrate with subsynovial tissue to address the root cause of lameness and osteoarthritis in dogs, cats, and horses — rather than masking symptoms. The underlying platform rests on proprietary thermoplastic protein-based biomaterials developed originally at Gel-Del Technologies (acquired via merger in 2017), protected by 19 granted patents and 8 pending applications, with a pipeline of 17 additional products at various development stages.

PetVivo generates revenue primarily through B2B sales of Spryng syringes to licensed veterinarians via a direct field sales team of Regional Business Development Managers and a multi-channel distributor network that includes Covetrus North America, Vedco, Clipper Distributing, Nupsala Limited, Eq Especialidades, and Veterinary Growth Partners. Pricing is quote-based and not publicly disclosed; sales follow a pay-as-you-go billing cadence. The company has achieved distribution across 600+ veterinary clinics in 49 states. A secondary revenue stream comes from licensing and partnership agreements, including an exclusive 10-year license for AgenticPet AI technology from Digital Landia Corp. and an exclusive sales and marketing agreement with VetStem for PrecisePRP canine and equine products. In 2025 the company expanded its footprint through the acquisition of PiezoBioMembrane (transformative biomaterials platform build), rebranded its operating subsidiary to PetVivo Animal Health, Inc., and uplisted to the OTCQX Best Market, while securing partnerships in equine wellness (Commonwealth), Latin America (Eq Especialidades), and national media (New to The Street).

Name

PetVivo Holdings

Legal name

PetVivo Holdings, Inc.

Website

https://petvivo.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

PetVivo Holdings develops and commercializes intra-articular injectable veterinary medical devices, led by Spryng with OsteoCushion Technology, for managing lameness and osteoarthritis in companion animals, sold to over 600 veterinary clinics in 49 states.

Ownership category

akta.pro rank

Product category

Veterinary Medical Devices

NAICS

Veterinary Services (54194), Veterinary Services (541940)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Surgical & Procedural Instruments (Scalpels, Forceps, Retractors) (HLAMAFAA)

akta.pro secondary industries

Veterinary Regenerative Medicine Manufacturing (GMP/CDMO, Cell Processing) (HLAMANAI), Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

• Veterinary medical devices
• Companion animal therapeutics
• Biomaterials technology
• Osteoarthritis treatment
• Intra-articular injectables

Headquarters

HQ city

Edina

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Spryng Product Sales: Sale of Spryng with OsteoCushion Technology intra-articular injectable veterinary medical devices for the management of lameness, joint pain and osteoarthritis in companion animals (dogs, cats, horses). Sold directly to veterinarians through field sales team and distribution partners.
2. Licensing and Partnership Revenue: Revenue from licensing agreements including the exclusive 10-year licensing agreement with Digital Landia for AgenticPet AI technology, and technology licensing arrangements with partners.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels6 records

Core offering

PetVivo Holdings manufactures and commercializes Spryng with OsteoCushion Technology, an intra-articular injectable veterinary medical device composed of sterilized extra-cellular matrix microparticles used to manage lameness, joint pain and osteoarthritis in companion animals (dogs, cats, horses). The product is sold to licensed veterinarians and veterinary clinics through a direct field sales team and veterinary distribution partners, with national distribution reaching over 600 clinics across 49 US states.

Product overview

PetVivo Holdings is a biomedical device company focused on manufacturing, commercializing, and licensing innovative medical devices and therapeutics for companion animals. The company's flagship product is Spryng® with OsteoCushion® Technology, an intra-articular injectable veterinary medical device for managing lameness, joint pain, and osteoarthritis in dogs, cats, and horses. The technology is based on proprietary thermoplastic protein-based biomaterials with 19 patents. The company also holds an exclusive 10-year license for AgenticPet AI (multi-agent autonomous AI for pet care) and sells PrecisePRP products through a VetStem partnership. PetVivo operates as the parent holding company with subsidiary PetVivo Animal Health, Inc.

Differentiator

Problem solved

Functional benefit

Brands

• Spryng with OsteoCushion Technology: Veterinary medical device - intra-articular injectable for management of lameness, joint pain and osteoarthritis in companion animals
• AgenticPet
• PetVivo AI

Products and services

• Spryng with OsteoCushion Technology An intra-articular injectable veterinary medical device that uses proprietary, patented micro-cushion technology to aid in the management of afflictions related to lameness, joint pain and osteoarthritis (OA) in companion animals (dogs, cats, horses). The sterilized extra-cellular matrix microparticles absorb onto the joint synovial lining and integrate with the subsynovial tissue to address the root cause of cartilage damage. Sold to licensed veterinarians for administration.
• AgenticPet AI Autonomous pet AI ecosystem using self-learning multi-agent AI technology for animal communication and pet care transformation. Licensed exclusively by PetVivo from Digital Landia under a 10-year agreement. Marketed as reducing veterinary client acquisition costs by 50-90%.
• PrecisePRP Canine and Equine Products Platelet-rich plasma (PRP) products for canine and equine animals, sold exclusively through PetVivo's sales and marketing agreement with VetStem as a complement to the Spryng product line.

Quantifiable outcome

• Published peer-reviewed clinical study in Veterinary Record evaluating Spryng safety and efficacy
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Eleven partnerships are on record, tiered minor and core.

• Veterinary Growth PartnersminorChannel Partner/ Reseller/ Distributor · 16 October 2025Vendor partner agreement with Veterinary Growth Partners to expand access to innovative veterinary therapeutics.
• New to The StreetcoreGTM or Marketing Partner · 9 October 202512-month national media campaign including TV commercials in NYC market, iconic outdoor advertising, and influencer program to increase brand awareness.
• Nupsala LimitedminorChannel Partner/ Reseller/ Distributor · 2 September 2025Distribution agreement with Nupsala Limited for international product distribution.
• CommonwealthcoreStrategic or Co-development Partner · 6 June 2025Partnership to advance equine wellness across thoroughbred racing, promoting the use of Spryng technology in performance horses.
• PiezoBioMembrane Inc.coreStrategic or Co-development Partner · 22 May 2025Master Services Agreement to jointly develop innovative functional biomaterials. Later acquired as transformative acquisition to build leading functional biomaterials platform.
• Eq EspecialidadesminorChannel Partner/ Reseller/ Distributor · 16 April 2025Distribution agreement with Eq Especialidades for equine veterinary products, expanding market presence in Latin America.
• Digital Landia Corp.coreStrategic or Co-development Partner · 3 March 2025Groundbreaking strategic alliance to pioneer Agentic AI for animal communication. Includes exclusive 10-year licensing agreement for AgenticPet AI technology. PetVivo AI, Inc. launched AI platform reducing veterinary client acquisition costs by 50-90%.
• VetStemminorChannel Partner/ Reseller/ Distributor · 14 February 2025Exclusive sales and marketing agreement for PrecisePRP canine and equine products, complementing the Spryng product line.
• Vedco, Inc.minorChannel Partner/ Reseller/ Distributor · 10 January 2025Partnership engagement with Vedco, Inc. for distribution of veterinary products.
• Clipper Distributing, LLCminorChannel Partner/ Reseller/ Distributor · 10 January 2025Partnership engagement with Clipper Distributing for veterinary product distribution.
• Covetrus North America, LLCcoreChannel Partner/ Reseller/ Distributor · 22 December 2023Distribution agreement with major veterinary distributor Covetrus North America for nationwide distribution of Spryng products to veterinary clinics across the United States.

Scale indicators11 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Ardent Animal Health: Provider of regenerative medicine and stem cell therapy services for companion animals, particularly dogs and cats with osteoarthritis and joint disease. Competes with PetVivo's Spryng in the same intra-articular joint treatment category for veterinarians.
• VetStem Biopharma: Veterinary regenerative medicine company offering stem cell therapy for dogs, cats, and horses with joint and orthopedic conditions. Directly comparable to PetVivo as a regenerative/cell-based therapy provider in companion animal joint health, and an existing commercial partner of PetVivo via the PrecisePRP agreement.
• Kinetic Vet: Equine-focused veterinary health company offering joint therapies and regenerative products for performance horses. Directly comparable to PetVivo's equine segment, including the thoroughbred racing partnership focus.

Broad incumbents

• Elanco Animal Health: Major animal health company with a broad portfolio including joint health products for companion animals. Represents an incumbent competitor with significantly larger commercial resources than PetVivo.
• Zoetis: Largest global animal health company offering pharmaceuticals, biologics, and devices for companion and livestock animals including osteoarthritis treatments. Sets competitive context for Spryng via its broad portfolio and distribution reach.
• Dechra Pharmaceuticals: Specialty animal health pharmaceutical company with a portfolio that includes orthopedic and pain management products for companion animals. Comparable as a broader incumbent in veterinary joint care therapeutics.
• Vetoquinol: Global animal health pharmaceutical company with a companion animal portfolio including pain management and joint care products. Comparable as an incumbent competitor in veterinary osteoarthritis therapeutics.
• IDEXX Laboratories: Leading veterinary diagnostics and software company serving companion animal practices. Comparable as a broad incumbent enabling veterinary clinic operations, including the customer base PetVivo sells into.

Emerging players

• Sentrx Animal Care: Developer of regenerative biomaterials for veterinary use, including intra-articular treatments for osteoarthritis in companion animals. Closely comparable to PetVivo's protein biomaterial approach for joint disease.
• Gallant Therapeutics: Veterinary stem cell therapy company offering FDA-reviewed stem cell treatments for dogs with osteoarthritis and other conditions. Competes in the same regenerative joint health category with a similar clinic-administered delivery model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/petvivo
• Facebookfacebook.com/petvivo

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries4 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PetVivo Holdings